Abstract We determined the status of vascular kallikrein in rats with severe hypertension caused by treatment with deoxycorticosterone acetate (DOCA) and drinking of 1% N a d for 6 weeks. We assayed active and total kininogenase (kallikrein) activity in the perfusate and in arterial and venous tissue. DOCA-salt rats had higher systolic blood pressure at 6 weeks (214±5 mm Hg) than rats drinking tap water (135±4 mm Hg) or saline (145±8 mm Hg). Kininogenase in the perfusate (nanograms bradykinin per minute per kilogram body weight) increased significantly at 2 weeks, from 5.8±2.1 to 8.9±1.4 for active kallikrein and from 28.7±0.4 to 48.7±2.9 for total kallikrein. Total kallikrein returned to control values at 4 weeks, whereas it was significantly reduced at 6 weeks (20.9±0.7). Active kallikrein was significantly depressed at 4 and 6 weeks (1.08±0.1 and 0.85±0.1, respectively [P<.05]). Active kallikrein in arterial tissue (picograms bradykinin per milligram per minute) showed a small but significant increase at 2 weeks, from 156±7 to 201 ±10 (P<.05), finally decreasing significantly by 6 weeks to 64±3; however, total kallikrein showed a significant decrease only at 6 weeks, from 844±17 to All±21. Both active and total kallikrein in the veins were higher than control values at 2 weeks, changing from 437±7 to 541±19 and from 1619±17 to 2062±86, respectively. Venous kallikrein remained elevated until the end of the experiment. These findings suggest that mineralocorticoids increase vascular kallikrein and that established hypertension lowers both arterial kallikrein and kallikrein released by the vasculature, whereas venous kallikrein is under a different regulatory control. The vascular kallikrein-kinin system may help counteract the elevation of vascular resistance in the earliest stages of DOCA-salt hypertension. Kinins are released from kininogen by the proteolytic action of kallikrein, and their potent vasodilator activity is mainly due to the release of prostaglandins, nitric oxide, and other endothelium-derived vasodilators. However, kinins circulate at very low concentrations and are rapidly hydrolyzed by a group of peptidases known as kininases. Thus, it has been postulated that if kinins participate in the regulation of BP, they must be released as paracrine hormones at or near the arterial wall. 2 We have previously shown that kallikrein, a potent kininogenase, is present in and released from blood vessels.
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Methods
All procedures involving animals were in accordance with institutional guidelines for animal experimentation. Male Wistar rats weighing 180 to 200 g were anesthetized with ether, and the left kidney was removed via a left flank incision. Three days later, the animals were randomly divided into three treatment groups, and the right kidney was removed with rats under ether anesthesia. The animals in group 1 (n=15) served as controls and were given free access to tap water. Group 2 (n=15) was given 1% (wt/vol) N a d Group 3 (n=70) drank 1% NaCl and received injections of DOCA (Sigma Chemical Co, St Louis, Mo; 25 mg/kg body wt IM) suspended in sesame seed oil twice a week. Animals were kept in a temperature-
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controlled room (20°C) illuminated between 8 AM and 8 PM. They were fed standard rat chow ad libitum, and systolic BP was determined by tail sphygmomanometry. Kallikrein activity in vascular tissues and in the perfusate of the isolated perfused hindquarters was measured 0, 2, 4, and 6 weeks after the beginning of the experiment.
Preparation of Tissue Homogenates
Male Wistar rats weighing 250 to 300 g were anesthetized with ether and decapitated. The thoracic and abdominal aorta, tail artery, thoracic segment of the inferior vena cava, and tail vein were removed and rinsed several times with ice-cold 0.01 mol/L Tris-HCl buffer (pH 7.4), 0.25 mol/L sucrose, and 3 mg/mL EDTA. After being cleaned of connective tissue and fat, the vessels were weighed, minced, and homogenized with 0.1 mol/L Tris-HCl buffer (pH 7.4).
The homogenate was centriifuged at 100Q? for 10 minutes, the supernatant separated out, and the pellet washed and centrifuged again at 2000g for 20 minutes. Both supernatants were pooled (final concentration, 100 mg wet tissue per milliliter) and kept at -20°C until needed for measurement of active and total kininogenase activity. 
Release of Kallikrein From the Isolated Perfused Rat Hindquarters
Rats were anesthetized with sodium pentobarbital (Nembutal, Abbott Laboratories) and given 1000 U heparin intravenously. After 3 minutes, the animal was decapitated to facilitate blood drainage. An abdominal incision was made, and the aorta and vena cava were carefully dissected from the renal vessels to the bifurcation. The rectum was cut between double ligatures and the distal sigmoid displaced to the upper abdomen. All major and minor tributaries of the descending aorta and abdominal vena cava were ligated except for the femoral and tail arteries. A 20-gauge catheter was placed in the aorta just below the renal arteries. The vena cava was also catheterized, and wanned (37°C) Krebs-Henseleit solution containing 3.5% Ficoll 70 and gassed with 95% Oj-5% CO 2 was perfused through the aorta. The buffer was passed through a 0.45 -jun filter before use. In the perfusion system, the medium was oxygenated by passage through the blood compartment of a C-DAK hollow-fiber artificial kidney (Cordis-Dow, Miami, Fla) and gassed with the O 2 -CO 2 mixture. The isolated hindquarters were perfused in a single-pass (non-recirculating) system using a peristaltic pump while perfusion pressure was constantly recorded. Details of the procedure were similar to those reported previously. 15 During the initial perfusion period, the hindquarters preparation was thoroughly rinsed with the buffer for 30 minutes until the effluent was consistently clear. The flow rate was adjusted to obtain the desired perfusion pressure, normally 60 to 80 mm Hg.
Kininogenase Activity
We measured active and total kininogenase activity by incubating 400 jiL of the homogenate supernatant (80 mg wet tissue), 1000 jiL of the medium in which the slices were bathed, or 1000 jiL of the hindquarters perfusate (previously concentrated five times) with 200 /iL of partially purified dog kininogen (2000 ng kinin-releasing capability) for 5 hours at 37°C in the presence of 1000 yiL fresh 0.1-mol/L Tris-HCl buffer (pH 8.5) containing EDTA (15 mg/mL), 1-10 phenanthroline (1 mg/mL), 8-OH-quinoline (1 mg/mL), and soybean trypsin inhibitor (SBTI) (100 jig/mL). Vascular kininogenase is inhibited by aprotinin and phenylmethylsulfonyl fluoride but is resistant to SBTI. SBTI was included in the incubation buffer to inhibit plasma kallikrein and trypsinlike enzymes that could contaminate the homogenates. Total kininogenase activity was measured by incubating 500 /iL homogenate with 20 /ig trypsin for 30 minutes at 37°C. The reaction was stopped by adding 100 jig SBTI, after which the homogenate was incubated with kininogen as described above for active kininogenase. Vascular kininogenase activity was expressed as the amount of kinins generated per milligram protein (or wet crude weight) per minute incubation with kininogen. Under these conditions, the kininogen itself released small amounts of kinins (kininogen blank). In every assay, duplicate tubes containing the reagents but no homogenates were assayed for kininogen blank. Vascular kininogenase activity was calculated as kininogenase activity in the sample minus kininogen blank. Kinins generated during incubation were measured by radioimmunoassay.
M
Results are expressed either per hour or as cumulative release during the total incubation time. The rate of release was determined by comparing slopes (activity/incubation time). We have previously found that kininogenase release is not due to tissue injury because release of a generalized cellular enzyme, lactic dehydrogenase, is small and follows a different pattern from kallikrein. 5 Proteins were determined as described before, 3 using albumin as a standard.
Statistical Analysis
For each data set, Dunnett's multiple-comparison procedure was used to compare the mean of each group (2,4, and 6 weeks) to week 0 (control). Within each data set, the overall significance level was .05. Independent t tests were carried out to compare mean experimental and control kallikrein release into the hindquarters perfusate. Wilcoxon's rank-sum test was used on the median at week 0 (control) because of the great disparity in variances at that time. Adjusting for multiple tests, P<.05/ 4=.O125. All results are expressed as mean±SEM. Fig 1 (top) shows changes in systolic BP in DOCAsalt rats (n=32). At the beginning of the experiment (week 0), BP was 135 ±2.1 mm Hg; at 2, 4, and 6 weeks it was 143±1.1, 172±1.2, and 214±3.9 mm Hg, respectively. These changes were statistically significant (P<.05). Active and total kininogenase released into the perfusate are shown in the bottom panel of Fig 1. At 2 weeks, active KK increased significantly from 5.8±2.1 to 8.9±1.4 and total KK from 28.7±0.4 to 48.7±2.9 ng bradykinin/min per kilogram body weight (P<.05). Total KK returned to control values at 4 weeks, whereas it was significantly reduced at 6 weeks (20.9±0.7). Active KK was significantly depressed at both 4 and 6 weeks (1.08±0.1 and 0.85±0.1, respectively [P<.05]). Total kallikrein released into the perfusate of normotensive controls that were drinking water (time control) did not change across time; KK values were 31.2±1.7,30.0±1.3, 32.5+1.7, and 33.0 ±1.3 at 0, 2, 4, and 6 weeks, respectively (P=NS). There were no differences between controls that were drinking water and rats drinking saline. When active and total KK in the perfusate of DOCA-salt rats were compared with time controls, significant differences were seen at 2 weeks (higher in DOCA-salt rats) and 6 weeks (lower in DOCA-salt rats) (P<.05). Active kininogenase in the arteries was significantly higher than initial values at 2 weeks. At 4 weeks, kininogenase did not differ from baseline (P=NS), whereas at 6 weeks it was significantly lower. Only at 6 weeks was total kininogenase (active plus inactive) significantly lower than initial values. Week*
Results
Aotlv. Total
Week* FIQ 1. Top: Une graph shows blood pressure In rats treated with deoxycortJcosterone acetate-salt; bottom: bar graph shows kininogenase activity in perfusate from isolated perfused hindquarters. Significant differences (P<.05, Dunnett's multiple comparison): blood pressure was higher at 6, 4, and 2 weeks than at time 0; active kininogenase, higher than controls at 2 weeks, lower than controls at 4 and 6 weeks; and total kallikrein, higher than controls at 2 weeks, lower than controls at 6 weeks. BK indicates bradykinin; BW, body weight. Both active and total kininogenase activity increased significantly after 2 weeks and remained high until the end of the experiment.
Discussion
We examined the status of vascular kininogenase (considered equivalent to vascular kallikrein) in rats during the development of DOCA-salt hypertension, using kininogenase activity in the effluent of isolated perfused rat hindquarters as an index of kallikrein released from vascular tissue. After treatment with DOCA-salt, we found that vascular kallikrein released into the perfusate initially increased but later returned to control values and was significantly reduced at the end of the experimental period. Total kallikrein showed only minor changes at the outset (P=NS) but subsequently decreased and was lowest at 6 weeks. In contrast, kallikrein in the veins showed a persistent increase. Thus, during the 6 weeks of DOCA-salt treatment used in this protocol, kallikrein in the perfusate showed a biphasic pattern. The decrease in arterial kallikrein during established DOCA-salt hypertension is in agreement with our previous findings in 1K1C hypertension. 13 In the present work we extended these findings and demonstrated that release is also lessened during hypertension. Therefore, because arterial kallikrein was found to decrease in two different models of experimental hypertension, the decrease in arterial content and vascular release of kallikrein is most likely secondary to high BP. On the other hand, the stimulated kallikrein release at 2 weeks of DOCA-salt treatment was unexpected. BP was only slightly elevated at this time. Kallikrein in the perfusate showed a profile similar to that of the arteries and distinct from that of the veins. Although the isolated perfused hindquarters technique does not allow us to determine the relative contribution of arteries and veins as sources of the
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kallikrein seen in the perfusate, the data suggest that it may reflect arterial release. Although release of kallikrein into the perfusate was clearly increased, the changes in arterial kallikrein content showed a similar tendency only for active kallikrein. Increased release with little change in content suggests that arterial kallikrein synthesis has increased as well. One possible explanation is that vascular kallikrein synthesis and release are heightened by mineralocorticoids, similar to renal kallikrein. 2 -6 -81216 The fact that venous kallikrein also increased during DOCA-salt treatment suggests that vascular kallikrein may respond to excess mineralocorticoids with increased synthesis.
The reasons for the decreased arterial kallikrein and vascular kallikrein release during hypertension are not clear. Decreased kallikrein concentration in the arterial wall may be partially due to hypertrophy secondary to hypertension, unaccompanied by a proportional increase in kallikrein activity; however, if that were the case, kallikrein release would have been constant. The fact that kallikrein released into the perfusate was also decreased suggests that the changes are not entirely due to dilution attributable to higher vascular mass. In addition, we do not know whether the vascular cells that release kallikrein into the perfusate are the same type we are measuring in vascular homogenates. We found mRNA coding for kallikrein in vascular smooth muscle cells in culture, 4 and Oza et al 17 found kallikrein activity in cultured vascular smooth muscle cells. This suggests that the kallikrein in the perfusate originated in the smooth muscle. Furthermore, although the existence of an endothelial KK system has been suggested, no firm evidence has been shown. 18 As we found previously in 1K1C hypertension, venous kallikrein is increased in DOCA-salt hypertension. It is not clear how venous kallikrein is regulated during hypertension. A possible link is that 1K1C and DOCA-salt models are both volume-expanded.
The role of the vascular KK system in regulating vascular resistance remains speculative. Majima et al 13 reported that hypertension developed faster in DOCAsalt-treated Brown Norway Katholiek rats with kininogen deficiency and in normal DOCA-salt-treated rats receiving aprotinin, a nonspecific but effective blocker of kallikrein activity. However, final BP levels were no different in DOCA controls or kininogen-deficient rats. Thus, during DOCA-salt treatment, absence or blockade of endogenous kinin production removes an antihypertensive mechanism. In control animals having an intact KK system, the antihypertensive effect delays development but is not important in setting final BP levels. The reason for this loss of antihypertensive activity is not clear. Although Majima suggested that increased activity of renal kallikrein and kinin may be responsible for the antihypertensive effects, the present results suggest that the vascular KK system could also play a role. It is possible that increased vascular kallikrein in the early stages resulted in increased local vasodilator activity, thus counteracting the rise in BP. As hypertension developed, kallikrein release decreased, possibly explaining the lack of a more sustained antihypertensive effect. The present data are consistent with the hypothesis that BP control is the result of a balance between vasopressor and vasodepressor influences. The vascular KK system may act as a vasodepressor. 
